

Lai Shan Tam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/674958/publications.pdf>

Version: 2024-02-01

295
papers

10,969
citations

28274

55
h-index

45317

90
g-index

302
all docs

302
docs citations

302
times ranked

11895
citing authors

#	ARTICLE	IF	CITATIONS
1	Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: Implications for Th17-mediated inflammation in auto-immunity. <i>Clinical Immunology</i> , 2008, 127, 385-393.	3.2	457
2	The 1-Year Impact of Severe Acute Respiratory Syndrome on Pulmonary Function, Exercise Capacity, and Quality of Life in a Cohort of Survivors. <i>Chest</i> , 2005, 128, 2247-2261.	0.8	294
3	Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1295-1302.	0.9	275
4	Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. <i>Lupus</i> , 2001, 10, 93-96.	1.6	244
5	Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. <i>Rheumatology</i> , 2008, 47, 718-723.	1.9	225
6	Accrual of organ damage over time in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2003, 30, 1955-9.	2.0	218
7	Imbalance of Th1/Th2 transcription factors in patients with lupus nephritis. <i>Rheumatology</i> , 2006, 45, 951-957.	1.9	203
8	Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2007, 26, 1495-1498.	2.2	192
9	IL33: Roles in Allergic Inflammation and Therapeutic Perspectives. <i>Frontiers in Immunology</i> , 2019, 10, 364.	4.8	191
10	Serum and Urinary Cell-free MiR-146a and MiR-155 in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2010, 37, 2516-2522.	2.0	174
11	Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus. <i>Lupus</i> , 2011, 20, 829-836.	1.6	174
12	Pathogenesis of ankylosing spondylitis. <i>Nature Reviews Rheumatology</i> , 2010, 6, 399-405.	8.0	169
13	Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 209-215.	0.9	160
14	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.9	158
15	Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: Association with human papillomavirus infection. <i>Arthritis and Rheumatism</i> , 2004, 50, 3619-3625.	6.7	145
16	Serum and urinary free microRNA level in patients with systemic lupus erythematosus. <i>Lupus</i> , 2011, 20, 493-500.	1.6	142
17	ABCG2 Polymorphism Is Associated With the Low-Density Lipoprotein Cholesterol Response to Rosuvastatin. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 558-562.	4.7	134
18	Subclinical carotid atherosclerosis in patients with psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2008, 59, 1322-1331.	6.7	126

#	ARTICLE	IF	CITATIONS
19	Elevated Production of B Cell Chemokine CXCL13 is Correlated with Systemic Lupus Erythematosus Disease Activity. <i>Journal of Clinical Immunology</i> , 2010, 30, 45-52.	3.8	120
20	Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2005, 44, 989-994.	1.9	119
21	Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. <i>Scandinavian Journal of Rheumatology</i> , 2002, 31, 296-300.	1.1	117
22	Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. <i>Rheumatology</i> , 2008, 47, 1678-1681.	1.9	115
23	Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. <i>Lupus</i> , 2004, 13, 601-604.	1.6	105
24	Plasma DNA aberrations in systemic lupus erythematosus revealed by genomic and methylomic sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E5302-11.	7.1	105
25	Leflunomide in the treatment of rheumatoid arthritis. <i>Clinical Therapeutics</i> , 2004, 26, 447-459.	2.5	102
26	The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study. <i>Frontiers in Medicine</i> , 2021, 8, 743180.	2.6	100
27	Glomerular and tubulointerstitial miR-638, miR-198 and miR-146a expression in lupus nephritis. <i>Nephrology</i> , 2012, 17, 346-351.	1.6	99
28	Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis?. <i>Rheumatology</i> , 2014, 53, 1108-1119.	1.9	98
29	Elevation of plasma osteopontin concentration is correlated with disease activity in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2005, 44, 602-606.	1.9	93
30	Effects of inflammatory cytokine IL-27 on the activation of fibroblast-like synoviocytes in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2010, 12, R129.	3.5	92
31	The impact of flare on disease costs of patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 61, 1159-1167.	6.7	85
32	Cost of illness studies in systemic lupus erythematosus: A systematic review. <i>Arthritis Care and Research</i> , 2011, 63, 751-760.	3.4	84
33	The gene expression of type 17 T-helper cell-related cytokines in the urinary sediment of patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2009, 48, 1491-1497.	1.9	79
34	CXCL 9 and CXCL 10 as Sensitive Markers of Disease Activity in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 257-264.	2.0	78
35	Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2012, 31, 435-440.	2.2	77
36	Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. <i>Thorax</i> , 2016, 71, 64-72.	5.6	77

#	ARTICLE	IF	CITATIONS
37	Warfarin interactions with Chinese traditional medicines: danshen and methyl salicylate medicated oil. <i>Australian and New Zealand Journal of Medicine</i> , 1995, 25, 258-258.	0.5	76
38	Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 2882-2890.	6.7	73
39	Intrarenal cytokine gene expression in lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 886-892.	0.9	72
40	Safety and efficacy of <i>Ganoderma lucidum</i> (lingzhi) and San Miao San supplementation in patients with rheumatoid arthritis: A double-blind, randomized, placebo-controlled pilot trial. <i>Arthritis and Rheumatism</i> , 2007, 57, 1143-1150.	6.7	71
41	Natural History of Cervical Papilloma Virus Infection in Systemic Lupus Erythematosus – A Prospective Cohort Study. <i>Journal of Rheumatology</i> , 2010, 37, 330-340.	2.0	71
42	Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. <i>Gut</i> , 2020, 69, 617-629.	12.1	71
43	Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus. <i>Clinical and Experimental Immunology</i> , 2002, 130, 345-351.	2.6	69
44	Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 1326-1331.	6.7	69
45	Anti-inflammatory activities of Chinese herbal medicine sinomenine and Liang Miao San on tumor necrosis factor- α -activated human fibroblast-like synoviocytes in rheumatoid arthritis. <i>Journal of Ethnopharmacology</i> , 2011, 137, 457-468.	4.1	69
46	Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus. <i>Clinical and Experimental Immunology</i> , 2009, 159, 11-22.	2.6	68
47	Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?. <i>Rheumatology</i> , 2009, 48, 892-898.	1.9	64
48	Repair of Bone Erosion in Rheumatoid Arthritis by Denosumab: A High-Resolution Peripheral Quantitative Computed Tomography Study. <i>Arthritis Care and Research</i> , 2017, 69, 1156-1163.	3.4	64
49	Long-term treatment of lupus nephritis with cyclosporin A. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1998, 91, 573-580.	0.5	63
50	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2018, 17, 1153-1168.	5.8	62
51	Elevated gene expression of Th1/Th2 associated transcription factors is correlated with disease activity in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2007, 34, 89-96.	2.0	62
52	High Prevalence of Asymptomatic Vertebral Fractures in Chinese Women with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 1646-1652.	2.0	60
53	Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. <i>British Journal of Rheumatology</i> , 2003, 42, 117-122.	2.3	59
54	2018 APLAR axial spondyloarthritis treatment recommendations. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 340-356.	1.9	59

#	ARTICLE	IF	CITATIONS
55	Increased arterial stiffness correlated with disease activity in systemic lupus erythematosus. <i>Lupus</i> , 2008, 17, 1096-1102.	1.6	58
56	Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users. <i>Rheumatology</i> , 2020, 59, 2340-2349.	1.9	58
57	Oral Prednisolone in the Treatment of Acute Gout. <i>Annals of Internal Medicine</i> , 2016, 164, 464.	3.9	57
58	Immunopathological Roles of Cytokines, Chemokines, Signaling Molecules, and Pattern-Recognition Receptors in Systemic Lupus Erythematosus. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-14.	3.3	56
59	Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 417-418.	0.9	55
60	Acupuncture in the treatment of rheumatoid arthritis: a double-blind controlled pilot study. <i>BMC Complementary and Alternative Medicine</i> , 2007, 7, 35.	3.7	55
61	Infliximab is Associated with Improvement in Arterial Stiffness in Patients with Early Rheumatoid Arthritis – A Randomized Trial. <i>Journal of Rheumatology</i> , 2012, 39, 2267-2275.	2.0	55
62	Systemic lupus erythematosus with neuropsychiatric manifestation incurs high disease costs: a cost-of-illness study in Hong Kong. <i>Rheumatology</i> , 2008, 48, 564-568.	1.9	54
63	Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 705-706.	0.9	53
64	High Prevalence of Subclinical Left Ventricular Dysfunction in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 1363-1370.	2.0	53
65	Cardiovascular Risk in Patients with Psoriatic Arthritis. <i>International Journal of Rheumatology</i> , 2012, 2012, 1-11.	1.6	53
66	Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis. <i>Frontiers in Medicine</i> , 2018, 4, 262.	2.6	53
67	Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. <i>Rheumatology</i> , 2008, 47, 1358-1363.	1.9	50
68	Gene expression of TWEAK/Fn14 and IP α 10/CXCR3 in glomerulus and tubulointerstitium of patients with lupus nephritis. <i>Nephrology</i> , 2011, 16, 426-432.	1.6	50
69	Elevated Expression and Pro-Inflammatory Activity of IL-36 in Patients with Systemic Lupus Erythematosus. <i>Molecules</i> , 2015, 20, 19588-19604.	3.8	50
70	Urine protein-to-creatinine ratio in an untimed urine collection is a reliable measure of proteinuria in lupus nephritis. <i>Rheumatology</i> , 2006, 46, 649-652.	1.9	49
71	Psoriatic arthritis in Asia. <i>Rheumatology</i> , 2009, 48, 1473-1477.	1.9	47
72	Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice. <i>Clinical and Experimental Immunology</i> , 2015, 181, 253-266.	2.6	47

#	ARTICLE	IF	CITATIONS
73	The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1534-1540.	0.7	46
74	Costs and quality of life of patients with ankylosing spondylitis in Hong Kong. <i>Rheumatology</i> , 2008, 47, 1422-1425.	1.9	46
75	Structure and strength of the distal radius in female patients with rheumatoid arthritis: A case-control study. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 794-806.	2.8	46
76	Loss of bone mineral density in Chinese pre-menopausal women with systemic lupus erythematosus treated with corticosteroids. <i>British Journal of Rheumatology</i> , 1998, 37, 405-410.	2.3	45
77	Alterations of Bone Density, Microstructure, and Strength of the Distal Radius in Male Patients With Rheumatoid Arthritis: A Case-Control Study With HR-pQCT. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 2118-2129.	2.8	45
78	The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis—a randomized, placebo-controlled pilot trial. <i>Rheumatology</i> , 2014, 53, 1065-1074.	1.9	45
79	Testing scaling assumptions, reliability and validity of medical outcomes study short-form 36 health survey in psoriatic arthritis. <i>Rheumatology</i> , 2010, 49, 1495-1501.	1.9	44
80	Alterations of bone geometry, density, microarchitecture, and biomechanical properties in systemic lupus erythematosus on long-term glucocorticoid: a caseâ€“control study using HR-pQCT. <i>Osteoporosis International</i> , 2013, 24, 1817-1826.	3.1	44
81	Imaging of sacroiliitis: Current status, limitations and pitfalls. <i>Quantitative Imaging in Medicine and Surgery</i> , 2019, 9, 318-335.	2.0	44
82	Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. <i>Rheumatology</i> , 2021, 60, 2109-2121.	1.9	44
83	Severe Acute Respiratory Syndrome: Correlation between Clinical Outcome and Radiologic Features. <i>Radiology</i> , 2004, 233, 579-585.	7.3	43
84	Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1237-1244.	0.9	43
85	Messenger RNA expression of podocyte-associated molecules in urinary sediment of patients with lupus nephritis. <i>Journal of Rheumatology</i> , 2007, 34, 2358-64.	2.0	43
86	Rapid improvement in rheumatoid arthritis patients on combination of methotrexate and infliximab: clinical and magnetic resonance imaging evaluation. <i>Clinical Rheumatology</i> , 2007, 26, 941-946.	2.2	42
87	Socioeconomic Burden of Psoriatic Arthritis in Hong Kong: Direct and Indirect Costs and the Influence of Disease Pattern. <i>Journal of Rheumatology</i> , 2010, 37, 1214-1220.	2.0	42
88	Measuring Disease Activity in Psoriatic Arthritis. <i>International Journal of Rheumatology</i> , 2012, 2012, 1-10.	1.6	42
89	Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 634-637.	1.5	41
90	Relationship Between Flare and Health-related Quality of Life in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2010, 37, 568-573.	2.0	41

#	ARTICLE	IF	CITATIONS
91	Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial. <i>Scandinavian Journal of Rheumatology</i> , 2011, 40, 411-421.	1.1	41
92	Increase in ventricular-arterial stiffness in patients with psoriatic arthritis. <i>Rheumatology</i> , 2012, 51, 2215-2223.	1.9	40
93	Cumulative inflammatory burden is independently associated with increased arterial stiffness in patients with psoriatic arthritis: a prospective study. <i>Arthritis Research and Therapy</i> , 2015, 17, 75.	3.5	40
94	Pattern and trend of five major musculoskeletal disorders in China from 1990 to 2017: findings from the Global Burden of Disease Study 2017. <i>BMC Medicine</i> , 2021, 19, 34.	5.5	40
95	Repeat Renal Biopsy in Lupus Nephritis: A Change in Histological Pattern Is Common. <i>American Journal of Nephrology</i> , 2011, 34, 220-225.	3.1	39
96	In vivo anti-inflammatory activities of novel cytokine IL-38 in Murphy Roths Large (MRL)/lpr mice. <i>Immunobiology</i> , 2017, 222, 483-493.	1.9	39
97	Involvement, satisfaction and unmet health care needs in patients with psoriatic arthritis. <i>Rheumatology</i> , 2008, 48, 53-56.	1.9	38
98	Urinary sediment ICAM-1 level in lupus nephritis. <i>Lupus</i> , 2012, 21, 1190-1195.	1.6	38
99	SLE disease per se contributes to deterioration in bone mineral density, microstructure and bone strength. <i>Lupus</i> , 2013, 22, 1162-1168.	1.6	38
100	Psoriatic arthritis as a distinct disease entity. <i>Journal of Postgraduate Medicine</i> , 2007, 53, 63-71.	0.4	38
101	Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. <i>Clinical Rheumatology</i> , 2011, 30, 303-312.	2.2	37
102	Plasma DNA Profile Associated with DNASE1L3 Gene Mutations: Clinical Observations, Relationships to Nuclease Substrate Preference, and In Vivo Correction. <i>American Journal of Human Genetics</i> , 2020, 107, 882-894.	6.2	37
103	The relationship between neuropsychiatric, clinical, and laboratory variables and quality of life of Chinese patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2008, 35, 1038-45.	2.0	37
104	Disease chronicity and activity predict subclinical left ventricular systolic dysfunction in patients with systemic lupus erythematosus. <i>Heart</i> , 2009, 95, 980-987.	2.9	36
105	Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease. <i>Lupus</i> , 2000, 9, 413-416.	1.6	34
106	Expression of T-bet, a type 1 T-helper cell transcription factor, in the urinary sediment of lupus patients predicts disease flare. <i>Rheumatology</i> , 2007, 46, 44-48.	1.9	34
107	Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid. <i>Arthritis Research and Therapy</i> , 2010, 12, R198.	3.5	34
108	Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis. <i>Translational Research</i> , 2016, 167, 138-151.	5.0	34

#	ARTICLE	IF	CITATIONS
109	Bone Mineral Density Change in Systemic Lupus Erythematosus: A 5-year Followup Study. <i>Journal of Rheumatology</i> , 2014, 41, 1990-1997.	2.0	33
110	Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis. <i>Rheumatology</i> , 2022, 61, 4437-4444.	1.9	33
111	Activation Profile of Intracellular Mitogen-Activated Protein Kinases in Peripheral Lymphocytes of Patients with Systemic Lupus Erythematosus. <i>Journal of Clinical Immunology</i> , 2009, 29, 738-746.	3.8	32
112	Risk factors for squamous intraepithelial lesions in systemic lupus erythematosus: A prospective cohort study. <i>Arthritis Care and Research</i> , 2011, 63, 269-276.	3.4	32
113	Aberrant expression of regulatory cytokine IL-35 in patients with systemic lupus erythematosus. <i>Lupus</i> , 2015, 24, 1257-1266.	1.6	32
114	IL-33 and soluble ST2 levels as novel predictors for remission and progression of carotid plaque in early rheumatoid arthritis: A prospective study. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 18-27.	3.4	32
115	High-Resolution Peripheral Quantitative Computed Tomography for Bone Evaluation in Inflammatory Rheumatic Disease. <i>Frontiers in Medicine</i> , 2020, 7, 337.	2.6	32
116	Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis. <i>Rheumatology</i> , 2018, 57, 563-571.	1.9	31
117	Analgesic and anti-arthritic effects of Lingzhi and San Miao San supplementation in a rat model of arthritis induced by Freund's complete adjuvant. <i>Journal of Ethnopharmacology</i> , 2008, 120, 44-50.	4.1	30
118	Urinary FOXP3 mRNA in patients with lupus nephritis--relation with disease activity and treatment response. <i>Rheumatology</i> , 2009, 48, 755-760.	1.9	29
119	Bone Density and Microarchitecture: Relationship Between Hand, Peripheral, and Axial Skeletal Sites Assessed by HR-pQCT and DXA in Rheumatoid Arthritis. <i>Calcified Tissue International</i> , 2012, 91, 343-355.	3.1	29
120	Evaluation of the CASPAR criteria for psoriatic arthritis in the Chinese population. <i>Rheumatology</i> , 2010, 49, 112-115.	1.9	28
121	Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2012, 14, R80.	3.5	28
122	Cortical thinning and progressive cortical porosity in female patients with systemic lupus erythematosus on long-term glucocorticoids: a 2-year case-control study. <i>Osteoporosis International</i> , 2015, 26, 1759-1771.	3.1	28
123	Intravenous cyclophosphamide improves cardiac dysfunction in lupus myocarditis. <i>Scandinavian Journal of Rheumatology</i> , 2003, 32, 306-308.	1.1	27
124	Mesangial lupus nephritis in Chinese is associated with a high rate of transformation to higher grade nephritis. <i>Lupus</i> , 2003, 12, 665-671.	1.6	27
125	SLICC/ACR damage index independently associated with left ventricular diastolic dysfunction in patients with systemic lupus erythematosus. <i>Lupus</i> , 2012, 21, 1057-1062.	1.6	27
126	Messenger RNA expression of RANTES in the urinary sediment of patients with lupus nephritis. <i>Nephrology</i> , 2006, 11, 219-225.	1.6	26

#	ARTICLE	IF	CITATIONS
127	Bone Microarchitecture Assessment by High-Resolution Peripheral Quantitative Computed Tomography in Patients with Systemic Lupus Erythematosus Taking Corticosteroids. <i>Journal of Rheumatology</i> , 2010, 37, 1473-1479.	2.0	26
128	Patients with systemic lupus erythematosus show increased platelet activation and endothelial dysfunction induced by acute hyperhomocysteinemia. <i>Journal of Rheumatology</i> , 2003, 30, 1479-84.	2.0	26
129	Hemiballismus in systemic lupus erythematosus: possible association with antiphospholipid antibodies. <i>Lupus</i> , 1995, 4, 67-69.	1.6	25
130	Immunomodulatory Effects of Lingzhi and San-Miao-San Supplementation on Patients with Rheumatoid Arthritis. <i>Immunopharmacology and Immunotoxicology</i> , 2006, 28, 197-200.	2.4	25
131	Latitude gradient influences the age of onset of rheumatoid arthritis: a worldwide survey. <i>Clinical Rheumatology</i> , 2017, 36, 485-497.	2.2	25
132	A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 954-962.	1.3	25
133	Comparison of 4 functional indexes in psoriatic arthritis with axial or peripheral disease subgroups using Rasch analyses. <i>Journal of Rheumatology</i> , 2008, 35, 1613-21.	2.0	25
134	Suppressive effect of combination treatment of leflunomide and methotrexate on chemokine expression in patients with rheumatoid arthritis. <i>Clinical and Experimental Immunology</i> , 2003, 133, 132-138.	2.6	24
135	Urinary mononuclear cell and disease activity of systemic lupus erythematosus. <i>Lupus</i> , 2006, 15, 262-267.	1.6	24
136	Societal costs of rheumatoid arthritis in Hong Kong: a prevalence-based cost-of-illness study. <i>Rheumatology</i> , 2011, 50, 1293-1301.	1.9	24
137	Activation of human fibroblast-like synoviocytes by uric acid crystals in rheumatoid arthritis. <i>Cellular and Molecular Immunology</i> , 2011, 8, 469-478.	10.5	24
138	Effect of Achieving Minimal Disease Activity on the Progression of Subclinical Atherosclerosis and Arterial Stiffness: A Prospective Cohort Study in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 271-280.	5.6	24
139	Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: A population-based study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 885-889.	3.4	24
140	Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 733-745.	1.9	24
141	Successful treatment with immunosuppression, anticoagulation and vasodilator therapy of pulmonary hypertension in SLE associated with secondary antiphospholipid syndrome. <i>Lupus</i> , 1998, 7, 495-497.	1.6	23
142	Lupus organ damage: what is damaged in Asian patients?. <i>Lupus</i> , 2010, 19, 1436-1441.	1.6	23
143	The alarmin functions of high-mobility group box-1 and IL-33 in the pathogenesis of systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 739-749.	3.0	23
144	Underestimation of Risk of Carotid Subclinical Atherosclerosis by Cardiovascular Risk Scores in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 218-226.	2.0	23

#	ARTICLE	IF	CITATIONS
145	Anti-inflammatory activities of <i>Ganoderma lucidum</i> (Lingzhi) and San-Miao-San supplements in MRL/lpr mice for the treatment of systemic lupus erythematosus. <i>Chinese Medicine</i> , 2016, 11, 23.	4.0	22
146	Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e97-e97.	0.9	22
147	Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong--the role of TNF blockers in an area of high tuberculosis burden. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, 679-85.	0.8	22
148	Serum Soluble Receptor for Advanced Glycation End Products Levels and Aortic Augmentation Index in Early Rheumatoid Arthritis--A Prospective Study. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 42, 333-345.	3.4	21
149	Members of the receptor for advanced glycation end products axis as potential therapeutic targets in patients with lupus nephritis. <i>Lupus</i> , 2015, 24, 675-686.	1.6	21
150	Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region. <i>Rheumatology</i> , 2019, 58, 803-810.	1.9	21
151	Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 717-722.	1.9	21
152	Density, structure, and strength of the distal radius in patients with psoriatic arthritis: the role of inflammation and cardiovascular risk factors. <i>Osteoporosis International</i> , 2015, 26, 261-272.	3.1	20
153	Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210895.	2.7	20
154	Decreased Expression of T Lymphocyte Co-Stimulatory Molecule CD26 on Invariant Natural Killer T Cells in Systemic Lupus Erythematosus. <i>Immunological Investigations</i> , 2009, 38, 350-364.	2.0	19
155	Down-Regulated NOD2 by Immunosuppressants in Peripheral Blood Cells in Patients with SLE Reduces the Muramyl Dipeptide-Induced IL-10 Production. <i>PLoS ONE</i> , 2011, 6, e23855.	2.5	19
156	DAPSA, carotid plaque and cardiovascular events in psoriatic arthritis: a longitudinal study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1320-1326.	0.9	18
157	Gut Microbiome and Its Interaction with Immune System in Spondyloarthritis. <i>Microorganisms</i> , 2020, 8, 1727.	3.6	18
158	Climatic influence on the prevalence of noncutaneous disease flare in systemic lupus erythematosus in Hong Kong. <i>Journal of Rheumatology</i> , 2008, 35, 1031-7.	2.0	18
159	The farnesoid X receptor -1G&T polymorphism influences the lipid response to rosuvastatin. <i>Journal of Lipid Research</i> , 2012, 53, 1384-1389.	4.2	17
160	Impaired Left Ventricular Apical Rotation is Associated with Disease Activity of Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 706-713.	2.0	17
161	Factors associated with withdrawal of the anti-TNF biologics in the treatment of rheumatic diseases: data from the H&K&B&R registry. <i>International Journal of Rheumatic Diseases</i> , 2014, 17, 1-8.	1.9	17
162	Huo-Luo-Xiao-Ling (HLXL)-Dan, a Traditional Chinese Medicine, for patients with osteoarthritis of the knee: a multi-site, randomized, double-blind, placebo-controlled phase II clinical trial. <i>Osteoarthritis and Cartilage</i> , 2015, 23, 2102-2108.	1.3	17

#	ARTICLE	IF	CITATIONS
163	Construct Validity of the Modified Numeric Rating Scale of Patient Global Assessment in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 844-848.	2.0	16
164	Carotid plaque and bone density and microarchitecture in psoriatic arthritis: the correlation with soluble ST2. <i>Scientific Reports</i> , 2016, 6, 32116.	3.3	16
165	Effect of biologics on radiographic progression of peripheral joint in patients with psoriatic arthritis: meta-analysis. <i>Rheumatology</i> , 2020, 59, 3172-3180.	1.9	16
166	Treatment of membranous lupus nephritis with prednisone, azathioprine and cyclosporin A. <i>Lupus</i> , 2001, 10, 827-829.	1.6	15
167	The influence of illness and variables associated with functional limitations in Chinese patients with ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2007, 34, 1032-9.	2.0	15
168	Estimation of glomerular filtration rate in patients with systemic lupus erythematosus. <i>Lupus</i> , 2006, 15, 276-281.	1.6	14
169	Increased Organ Damage Associated with Deterioration in Volumetric Bone Density and Bone Microarchitecture in Patients with Systemic Lupus Erythematosus on Longterm Glucocorticoid Therapy. <i>Journal of Rheumatology</i> , 2012, 39, 1955-1963.	2.0	14
170	Intrarenal and Urinary Th9 and Th22 Cytokine Gene Expression in Lupus Nephritis. <i>Journal of Rheumatology</i> , 2015, 42, 1150-1155.	2.0	14
171	A pilot evaluation of Arthritis Self-Management Program by lay leaders in patients with chronic inflammatory arthritis in Hong Kong. <i>Clinical Rheumatology</i> , 2016, 35, 935-941.	2.2	14
172	Effect of Treat-to-target Strategies Aiming at Remission of Arterial Stiffness in Early Rheumatoid Arthritis: A Randomized Controlled Study. <i>Journal of Rheumatology</i> , 2018, 45, 1229-1239.	2.0	14
173	Circulating miR-99b-5p as a novel predictor of erosion progression on high-resolution peripheral quantitative computed tomography in early rheumatoid arthritis: A prospective cohort study. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1724-1733.	1.9	14
174	The Perspective on Psoriatic Arthritis in Asia. <i>Current Rheumatology Reports</i> , 2011, 13, 369-375.	4.7	13
175	Relationship of Intrarenal Gene Expression and the Histological Class of Lupus Nephritis – A Study on Repeat Renal Biopsy. <i>Journal of Rheumatology</i> , 2012, 39, 1942-1947.	2.0	13
176	Labour and non-labour market productivity in Chinese patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2012, 51, 284-292.	1.9	13
177	Monitoring of urinary messenger RNA levels for the prediction of flare in systemic lupus erythematosus. <i>Clinica Chimica Acta</i> , 2012, 413, 448-455.	1.1	13
178	Development and Assessment of Users' Satisfaction with the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Website. <i>Journal of Rheumatology</i> , 2013, 40, 34-39.	2.0	13
179	Effect of treat-to-target strategies on bone erosion progression in early rheumatoid arthritis: An HR-pQCT study. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 374-383.	3.4	13
180	Minimal Important Difference and Responsiveness to Change of the SF-36 in Patients with Psoriatic Arthritis Receiving Tumor Necrosis Factor- α Blockers. <i>Journal of Rheumatology</i> , 2011, 38, 2077.2-2079.	2.0	12

#	ARTICLE	IF	CITATIONS
181	Predictors of functional deterioration in Chinese patients with Psoriatic arthritis: a longitudinal study. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 284.	1.9	12
182	Incidence of and risk factors for non-vertebral and vertebral fracture in female Chinese patients with systemic lupus erythematosus: a five-year cohort study. <i>Lupus</i> , 2014, 23, 854-861.	1.6	12
183	Dyslipidemia Is Related to Mortality in Critical Patients With Coronavirus Disease 2019: A Retrospective Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 611526.	3.5	12
184	Neurotoxicity following the ingestion of a Chinese medicinal plant, <i>Alocasia macrorrhiza</i> . <i>Human and Experimental Toxicology</i> , 1995, 14, 727-728.	2.2	11
185	Decreased ex vivo production of TNF- α and IL-8 by peripheral blood cells of patients with rheumatoid arthritis after infliximab therapy. <i>International Immunopharmacology</i> , 2007, 7, 1668-1677.	3.8	11
186	Evaluation of spinal mobility measurements in predicting axial psoriatic arthritis. <i>Clinical Rheumatology</i> , 2011, 30, 1157-1162.	2.2	11
187	Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: An Asian perspective. <i>Respirology</i> , 2013, 18, 765-773.	2.3	11
188	Successful treatment of pure red cell aplasia associated with systemic lupus erythematosus with oral danazol and steroid. <i>Rheumatology International</i> , 2005, 25, 388-390.	3.0	10
189	The socioeconomic burden of systemic lupus erythematosus: state-of-the-art and prospects. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 53-69.	1.4	10
190	Rationale and design of the screening of pulmonary hypertension in systemic lupus erythematosus (SOPHIE) study. <i>ERJ Open Research</i> , 2018, 4, 00135-2017.	2.6	10
191	Bone Mass, Microstructure, and Strength Can Discriminate Vertebral Fracture in Patients on Long-Term Steroid Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3340-3349.	3.6	10
192	Can the urine dipstick test reduce the need for microscopy for assessment of systemic lupus erythematosus disease activity?. <i>Journal of Rheumatology</i> , 2005, 32, 828-31.	2.0	10
193	Dynamic contrast-enhanced imaging of the wrist in rheumatoid arthritis: dedicated low-field (0.25-T) versus high-field (3.0-T) MRI. <i>Skeletal Radiology</i> , 2015, 44, 1095-1101.	2.0	9
194	Synoviocytes-derived Interleukin 35 Potentiates B Cell Response in Patients with Osteoarthritis and Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 563-573.	2.0	9
195	Progressive structural bone changes and their relationship with treatment in patients with psoriatic arthritis: a longitudinal HR-pQCT study. <i>Arthritis Research and Therapy</i> , 2019, 21, 265.	3.5	9
196	Comparison of bone structure and microstructure in the metacarpal heads between patients with psoriatic arthritis and healthy controls: an HR-pQCT study. <i>Osteoporosis International</i> , 2020, 31, 941-950.	3.1	9
197	A Microwave-Ultrasonic Cell for Sound-Speed Measurements in Liquids. <i>International Journal of Thermophysics</i> , 2005, 26, 1651-1665.	2.1	8
198	Clinical presentation, treatment and outcome of Takayasu's arteritis in southern Chinese: a multicenter retrospective study. <i>Rheumatology International</i> , 2018, 38, 2263-2270.	3.0	8

#	ARTICLE	IF	CITATIONS
199	The role of imaging in early diagnosis and prevention of joint damage in inflammatory arthritis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 499-511.	3.0	8
200	Risk of community-acquired pneumonia requiring hospitalization in patients with spondyloarthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2096261.	2.7	8
201	Cardiovascular disease and depression in psoriatic arthritis: Multidimensional comorbidities requiring multidisciplinary management. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101689.	3.3	8
202	Association of C-reactive protein and non-steroidal anti-inflammatory drugs with cardiovascular events in patients with psoriatic arthritis: a time-dependent Cox regression analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110277.	2.7	8
203	The Role of High-resolution Peripheral Quantitative Computed Tomography as a Biomarker for Joint Damage in Inflammatory Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 1911-1913.	2.0	7
204	No Systemic Lupus Erythematosus with COVID-19 in Hong Kong: The Effect of Masking?. <i>Journal of Rheumatology</i> , 2020, 47, 1591-1591.	2.0	7
205	Treat to target and prevention of subclinical atherosclerosis in psoriatic arthritis— which target should we choose?. <i>Rheumatology</i> , 2020, 59, 2881-2892.	1.9	7
206	Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 981-988.	0.9	7
207	Jagged Ends on Multinucleosomal Cell-Free DNA Serve as a Biomarker for Nuclease Activity and Systemic Lupus Erythematosus. <i>Clinical Chemistry</i> , 2022, 68, 917-926.	3.2	7
208	Use of telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak: The 6-month results of a randomized controlled trial. <i>Lupus</i> , 2022, 31, 488-494.	1.6	7
209	Stonefish sting: an occupational hazard in Hong Kong. <i>Annals of Tropical Medicine and Parasitology</i> , 1996, 90, 675-676.	1.6	6
210	ERAMRS: a new MR scoring system for early rheumatoid arthritis of the wrist. <i>European Radiology</i> , 2019, 29, 5646-5654.	4.5	6
211	Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group. <i>Journal of Rheumatology</i> , 2019, 46, 1406-1408.	2.0	6
212	Comparison of carotid artery ultrasound and Framingham risk score for discriminating coronary artery disease in patients with psoriatic arthritis. <i>RMD Open</i> , 2020, 6, e001364.	3.8	6
213	Vertebral body corner oedema vs gadolinium enhancement as biomarkers of active spinal inflammation in ankylosing spondylitis. <i>British Journal of Radiology</i> , 2012, 85, e702-e708.	2.2	5
214	Seasonal Effect on Disease Onset and Presentation in Anti-MDA5 Positive Dermatomyositis. <i>Frontiers in Medicine</i> , 2022, 9, 837024.	2.6	5
215	Urinary mRNA in Systemic Lupus Erythematosus. <i>Advances in Clinical Chemistry</i> , 2013, 62, 197-219.	3.7	4
216	Referral strategy for early recognition of axial spondyloarthritis: consensus recommendations from the Hong Kong Society of Rheumatology. <i>International Journal of Rheumatic Diseases</i> , 2013, 16, 500-508.	1.9	4

#	ARTICLE	IF	CITATIONS
217	Computer-Aided Assessment of Spinal Inflammation on Magnetic Resonance Images in Patients With Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1789-1797.	5.6	4
218	Infliximab in the Treatment of Refractory Ocular Inflammatory Diseases. <i>Asia-Pacific Journal of Ophthalmology</i> , 2015, 4, 19-24.	2.5	4
219	The causal effect of interleukin-17 on the risk of psoriatic arthritis: a Mendelian randomization study. <i>Rheumatology</i> , 2021, 60, 1963-1973.	1.9	4
220	Elevating the role of carers in rheumatoid arthritis management in the Asia-Pacific region. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 898-910.	1.9	3
221	MRI wrist in early rheumatoid arthritis: reduction in inflammation assessed quantitatively during treatment period correlates best with clinical improvement. <i>Skeletal Radiology</i> , 2021, 50, 1337-1345.	2.0	3
222	The role of imaging in predicting the development of rheumatoid arthritis. <i>Rheumatology and Immunology Research</i> , 2021, 2, 27-33.	0.8	3
223	Performance of the 2017 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria in Patients With Idiopathic Inflammatory Myopathy and Anti-Melanoma Differentiation-Associated Protein 5 Positivity. <i>Arthritis and Rheumatology</i> , 2022, 74, 1588-1592.	5.6	3
224	Correspondence on "No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related" physician-reported spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e187-e187.	0.9	3
225	Nonsteroidal anti-inflammatory drugs and cardiovascular disease risk in spondyloarthritis-spectrum diseases. <i>Current Opinion in Rheumatology</i> , 2022, 34, 203-208.	4.3	3
226	Metabolic abnormalities associated with microalbuminuria in systemic lupus erythematosus. <i>British Journal of Rheumatology</i> , 2001, 40, 1193-a-1194.	2.3	2
227	Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky045.	0.7	2
228	The Asia-Pacific Initiative for Rheumatology Nurse Education: Current gaps, programme development and future outlook. <i>Musculoskeletal Care</i> , 2020, 18, 397-403.	1.4	2
229	Serum Calprotectin Level Is Independently Associated With Carotid Plaque Presence in Patients With Psoriatic Arthritis. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	2
230	Maintenance treatment of proliferative lupus nephritis can be discontinued after remission in some patients. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 672-673.	2.0	1
231	The direct medical cost of rheumatoid arthritis in Hong Kong. <i>Journal of Medical Economics</i> , 2007, 10, 443-453.	2.1	1
232	FR10412...The effects of golimumab on the progression of subclinical atherosclerosis and arterial stiffness in patients with ankylosing spondylitis " a randomized, placebo- controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A513.1-A513.	0.9	1
233	THU0555...Immunopathological Roles of the Novel Anti-Inflammatory Cytokine Interleukin-35 in Patients with Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 374.2-374.	0.9	1
234	THU0033...Effects of Early Remission on Work Ability and Absenteeism in Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 189.2-189.	0.9	1

#	ARTICLE	IF	CITATIONS
235	SAT0073â€¦MIR-186-5P targeting IL-33 gene as biomarker to predict subclinical atherosclerosis in patients with early rheumatoid arthritis. , 2017, , .		1
236	FRI0523â€¦Short-term efficacy and safety of new biological agents targeting the IL-6, IL-12/23 and IL-17 pathways for active psoriatic arthritis: a network meta-analysis of randomised controlled trials. , 2017, , .		1
237	FRI0524â€¦Carotid atherosclerosis is associated with compromised volumetric bone mineral density and microstructures in patients with inflammatory arthritis. , 2017, , .		1
238	Inflammatory Burden Is Related to An Early Reduction of LV Functional Reserve in Psoriatic Arthritis. JACC: Cardiovascular Imaging, 2018, 11, 369-370.	5.3	1
239	Dr. Tam, et al, reply. Journal of Rheumatology, 2018, 45, 1330-1332.	2.0	1
240	OP0132â€¦Structural and microstructural intra-articular bone changes at the metacarpal heads in patients with psoriatic arthritis compared to controls: a hr-pqct study. , 2018, , .		1
241	Deception and self-harm in the quest for freedom: an audit of Vietnamese boat people admitted to a regional hospital in Hong Kong. Medical Journal of Australia, 1995, 163, 524-526.	1.7	1
242	FRI0552â€¦GLOBAL, REGIONAL, AND NATIONAL BURDEN OF LOW BACK PAIN, 1990-2019: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2019. Annals of the Rheumatic Diseases, 2020, 79, 877.1-878.	0.9	1
243	Factors Associated With Use of Telemedicine for Follow-Up of SLE in the COVID-19 Outbreak. Frontiers in Medicine, 2021, 8, 790652.	2.6	1
244	PAR13 THE DIRECT MEDICAL COST OF RHEUMATOID ARTHRITIS IN HONG KONG. Value in Health, 2005, 8, A27-A28.	0.3	0
245	P336 Subclinical left ventricular systolic dysfunction in patients with systemic lupus erythematosus (SLE). International Journal of Cardiology, 2008, 125, S61.	1.7	0
246	Are spot urine samples adequate for assessment of proteinuria in patients with lupus nephritis?. Nature Clinical Practice Nephrology, 2008, 4, 72-73.	2.0	0
247	General Cardiology 1. European Heart Journal Supplements, 2010, 12, S3-S4.	0.1	0
248	SAT0210â€¦Comparisons of bone microarchitecture and mechanical properties between childhood- and adult-onset patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2013, 71, 543.1-543.	0.9	0
249	THU0196â€¦Bone microarchitecture and biomechanical properties in chinese female patients with systemic lupus erythematosus damage. Annals of the Rheumatic Diseases, 2013, 71, 221.3-222.	0.9	0
250	THU0083â€¦Abnormal volumetric density and microarchitecture at the radius in chinese female patients with rheumatoid arthritis: A case-control study. Annals of the Rheumatic Diseases, 2013, 71, 181.1-181.	0.9	0
251	SAT0397â€¦Serum Apolipoprotein B is Associated with Increased Risk of the Presence and Progression of Carotid Atherosclerosis in Patients with Psoriatic Arthritis: Table 1.. Annals of the Rheumatic Diseases, 2014, 73, 738.1-738.	0.9	0
252	SAT0413â€¦A Case-Control Study of Density and Microstructure at the Distal Radius in Patients with Psoriatic Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 744.2-744.	0.9	0

#	ARTICLE	IF	CITATIONS
253	SAT0414â€¦Predictors of Functional Deterioration in Chinese Patients with Psoriatic Arthritis: A Longitudinal Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 744.3-745.	0.9	0
254	THU0570â€¦A Pilot Evaluation of Arthritis Self-Management Program by Lay Leaders in Patients with Chronic Inflammatory Arthritis in Hong Kong. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 379.3-380.	0.9	0
255	THU0383â€¦Aberrant Expression of Novel Pro-Inflammatory Cytokine Interleukin-36 in Patients with Systemic Lupus Erythematosus: A Cross-Sectional Study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 335.1-335.	0.9	0
256	THU0164â€¦Comparison of the Effect of Denosumab and Alendronate on Bone Density and Microarchitecture at the Distal Radius in Rheumatoid Arthritis Females with Low Bone Mass: A Randomized Controlled Trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 253.2-253.	0.9	0
257	AB0811â€¦Carotid Atherosclerosis is Associated with Compromised Volumetric Bone Mineral Density and Microstructure in Patients with Psoriatic Arthritis: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1170.3-1171.	0.9	0
258	AB0812â€¦Increased Arterial Stiffness is Associated with Compromised Volumetric Bone Mineral Density and Microstructure in Patients with Psoriatic Arthritis: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1171.1-1171.	0.9	0
259	Authorsâ€™ Reply to â€œInfliximab in the Treatment of Refractory Ocular Inflammatory Diseasesâ€. <i>Asia-Pacific Journal of Ophthalmology</i> , 2015, 4, 184.	2.5	0
260	AB0384â€¦Comparison of the Effect of Denosumab and Alendronate on Bone Density and Microarchitecture at the 2ND Metacarpal Head in Rheumatoid Arthritis Females with Low Bone Mass by High- Resolution Peripheral Quantitative Computer Tomography: A Randomized Controlled Pilot Trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1021.2-1021.	0.9	0
261	THU0184â€¦Repair of Bone Erosion in Rheumatoid Arthritis by Denosumab: An HR-pQCT Study.. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 251.3-252.	0.9	0
262	FRI0455â€¦All Cardiovascular (CV) Risk Scores Significantly Underestimated Cv Risk Defined by Carotid Ultrasound in Psoriatic Arthritis- Can We Improve Their Performances?. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 601.1-601.	0.9	0
263	FRI0034â€¦Rage Activity Influences Co-Development of Joint and Vascular Disease in RA. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 438.1-438.	0.9	0
264	SAT0141â€¦Changes of Bone Density and Microarchitecture in Rheumatoid Arthritis Patients with Early Disease: A One-Year Study with HR-PQCT: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 715.2-715.	0.9	0
265	SAT0532â€¦Tibial Cortical Thickness Measured by Highâ€œResolution Peripheral Quantitative Computed Tomography Discriminates Vertebral Fractures in Patients on Long-Term Glucocorticoids Independent of Areal Bone Mineral Density: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 862.1-862.	0.9	0
266	IMPAIRED LEFT VENTRICULAR LONGITUDINAL FUNCTIONAL RESERVE IN PATIENTS WITH PSORIATIC ARTHRITIS: A LOW-LEVEL BICYCLE ERGOMETER EXERCISE TEST. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1615.	2.8	0
267	AB1229-HPRâ€¦Evaluation of rheumatology nurse-led clinic in managing patients with rheumatoid arthritis: a retrospective study. , 2017, , .		0
268	SAT0479â€¦Increased carotid intima-media thickness can discriminate significant coronary artery stenosis by coronary ct angiogram in patients with psoriatic arthritis. , 2017, , .		0
269	Frequent Conversion of Tuberculosis Screening Test During Anti-Tumour Necrosis Factor Therapy in Chinese Patients with Inflammatory Bowel Disease: A Prospective Study with 3 Years Follow-Up. <i>Gastroenterology</i> , 2017, 152, S387.	1.3	0
270	AB0424â€¦The effect of high level of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with early rheumatoid arthritisâ€œ a cross-sectional and longitudinal analysis. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
271	AB0221â€¦Impact of small to medium dose of prednisolone on bone mineral density among early rheumatoid arthritis patients. , 2017, , .		0
272	FRI0576â€¦Comparing treatment indication by frax and bmd alone in rheumatic patients on long-term glucocorticoid in hong kong. , 2017, , .		0
273	SAT0747-HPRâ€¦Can achieving sustained das remission prevent progression of sub-clinical atherosclerosis? a prospective cohort study in early rheumatoid arthritis (ERA). , 2017, , .		0
274	THU0078â€¦Berberine ameliorates bone erosions in collagen-induced arthritis rat models via suppressing the expression of il-17a. , 2018, , .		0
275	Comment on: Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis: reply. Rheumatology, 2018, 57, 2062-2062.	1.9	0
276	Authors reply to comment on axial SpA recommendations. International Journal of Rheumatic Diseases, 2019, 22, 1346-1347.	1.9	0
277	SAT0364â€¦EFFECT OF ACHIEVING DAPSA-LDA ON THE PROGRESSION OF BONE EROSION AND ENTHESIOPHYTES IN PATIENTS WITH PSORIATIC ARTHRITIS: A LONGITUDINAL HR-PQCT STUDY. , 2019, , .		0
278	THU0264â€¦ANALYSIS OF SURVIVAL ASSOCIATED WITH PULMONARY ARTERIAL HYPERTENSION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
279	FRI0464â€¦EFFECT OF BIOLOGICS ON ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. , 2019, , .		0
280	OP0346â€¦MRI OF THE WRIST IN EARLY RHEUMATOID ARTHRITIS AFTER 1-YEAR TREAT-TO-TARGET STRATEGY. , 2019, , .		0
281	Spondyloarthritis-Related Autoimmune Aortitis Complicated by Severe Aortic Regurgitation. Circulation: Cardiovascular Imaging, 2019, 12, e008341.	2.6	0
282	SAT0043â€¦il-33/st2-mediated inflammation in endothelial cell is directly aggravated by il-6 during lupus nephritis. , 2018, , .		0
283	FRI0616â€¦Cost-effectiveness of swapping strategy for established psoriatic arthritis and immediate versus standard swapping strategy for early psoriatic arthritis. , 2018, , .		0
284	SAT0094â€¦Physical function and health related quality of life in early rheumatoid arthritis patients who achieved only low disease activity compared with remission. , 2018, , .		0
285	THU0179â€¦Mir-382â€“5p targeting il-33 gene as biomarker to predict subclinical atherosclerosis progression in patients with early rheumatoid arthritis. , 2018, , .		0
286	FRI0032â€¦Role of ultrasound in assessing disease activity in patients with early rheumatoid arthritis treated by two treat-to-target strategies. , 2018, , .		0
287	AB1270â€¦Achieving early disease control and reducing indirect cost â€“ the crystal registry in hong kong rheumatoid arthritis patients. , 2018, , .		0
288	OP0127â€¦Can achieving minimal disease activity (MDA) prevent progression of subclinical atherosclerosis and arterial stiffness? a two-year prospective cohort study in psoriatic arthritis. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
289	SAT0309â€¦Underestimation of cardiovascular events by cardiovascular risk scores in psoriatic arthritis patients. , 2018, , .		0
290	SAT0656â€¦Circulating mir-99b-5p is a marker of inflammation and structural damage on mri in early rheumatoid arthritis. , 2018, , .		0
291	FRI0666â€¦Circulating mir-99b-5p as a predictor of erosion progression in early rheumatoid arthritis: a 1-year follow-up study by hr-pqct. , 2018, , .		0
292	FRI0565â€¦Eramrs: a new mr scoring system for early rheumatoid arthritis. , 2018, , .		0
293	Approaches to screening for latent tuberculosis infection in patients with immune-mediated disease prior to commencement of biologics. , 2020, 26, 93-94.		0
294	SAT0408â€¦UTILITY OF CAROTID ULTRASOUND AND FRAMINGHAM RISK SCORE ON DISCRIMINATING CORONARY ARTERY DISEASE IN PATIENTS WITH PSORIATIC ARTHRITIS (PsA). Annals of the Rheumatic Diseases, 2020, 79, 1156.2-1156.	0.9	0
295	The Temporal Trend of Disease Burden Attributable to Metabolic Factors in China, 1990-2019, an Analysis of the Global Burden of Disease Study. SSRN Electronic Journal, 0, , .	0.4	0